Metformin-induced increases in GDF15 are important for suppressing appetite and promoting weight loss

Autor: Gregory R. Steinberg, Natalia McInnes, Brennan K. Smith, Rachel Lu, Sibylle Hess, Emily A. Day, Pedrum Mohammadi-Shemirani, Andrew G. McArthur, Marisa R Morrow, Robert M Gutgesell, Amogelang R. Raphenya, Mostafa Kabiri, Guillaume Paré, Rebecca J. Ford, Hertzel C. Gerstein
Rok vydání: 2019
Předmět:
Zdroj: Nature Metabolism. 1:1202-1208
ISSN: 2522-5812
Popis: Metformin is the most commonly prescribed medication for type 2 diabetes, owing to its glucose-lowering effects, which are mediated through the suppression of hepatic glucose production (reviewed in refs. 1-3). However, in addition to its effects on the liver, metformin reduces appetite and in preclinical models exerts beneficial effects on ageing and a number of diverse diseases (for example, cognitive disorders, cancer, cardiovascular disease) through mechanisms that are not fully understood1-3. Given the high concentration of metformin in the liver and its many beneficial effects beyond glycemic control, we reasoned that metformin may increase the secretion of a hepatocyte-derived endocrine factor that communicates with the central nervous system4. Here we show, using unbiased transcriptomics of mouse hepatocytes and analysis of proteins in human serum, that metformin induces expression and secretion of growth differentiating factor 15 (GDF15). In primary mouse hepatocytes, metformin stimulates the secretion of GDF15 by increasing the expression of activating transcription factor 4 (ATF4) and C/EBP homologous protein (CHOP; also known as DDIT3). In wild-type mice fed a high-fat diet, oral administration of metformin increases serum GDF15 and reduces food intake, body mass, fasting insulin and glucose intolerance; these effects are eliminated in GDF15 null mice. An increase in serum GDF15 is also associated with weight loss in patients with type 2 diabetes who take metformin. Although further studies will be required to determine the tissue source(s) of GDF15 produced in response to metformin in vivo, our data indicate that the therapeutic benefits of metformin on appetite, body mass and serum insulin depend on GDF15.
Databáze: OpenAIRE